Auriga Starts Stock Coverage on Teva Pharmaceutical Industries Ltd (TEVA)

By admin | 6 years ago

Research analysts at Auriga began coverage on shares of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) in a report released on Wednesday. The firm set a “hold” rating and a $45.00 price target on the stock.

Shares of Teva Pharmaceutical Industries Ltd opened at 39.88 on Wednesday. Teva Pharmaceutical Industries Ltd has a one year low of $35.00 and a one year high of $51.15. The company has a market cap of $34.735 billion and a P/E ratio of 11.99.

Teva Pharmaceutical Industries Ltd last issued its quarterly earnings data on Wednesday, May 9th. The company reported $1.47 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.44 by $0.03. The company’s quarterly revenue was up 25.0% on a year-over-year basis. On average, analysts predict that Teva Pharmaceutical Industries Ltd will post $1.35 earnings per share next quarter.

A number of other firms have also recently commented on TEVA. Analysts at Zacks reiterated a “neutral” rating on shares of Teva Pharmaceutical Industries Ltd in a research note to investors on Friday, May 11st. They now have a $44.00 price target on the stock. Separately, analysts at Needham & Company downgraded shares of Teva Pharmaceutical Industries Ltd from a “strong-buy” rating to a “hold” rating in a research note to investors on Thursday, May 10th.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories.

About the author